Agios Pharmaceuticals, Inc. AGIO is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders.
The company has several interesting candidates in its pipeline. Its cancer pipeline comprises enasidenib (IDH2 mutant inhibitor), AG-120 (IDH1 mutant inhibitor) and AG-881 (pan-IDH mutant inhibitor).
Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221 and AG-881.
With no approved products in its portfolio, investor focus should remain on the company’s pipeline updates since a number of pipeline-related activities are lined up for the rest of 2016.
Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average miss of 80.87%.
AGIOS PHARMACT Price and EPS Surprise
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agios posted wider-than-expected loss in the third quarter of 2016. Our consensus called for a loss of $1.51 per share, and the company reported a loss of $1.63.
Revenues: Revenues in the reported quarter also came in below expectations. Agios posted revenues of approximately $9 million, compared to our consensus estimate of $10.8 million.
Key Stats: Agios continues to progress with its pipeline. Agios along with Celgene will submit a new drug application for enasidenib for the treatment of patients with relapsed and/or refractory acute myeloid leukemia by the end of 2016.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment